Anti-IGF-1 receptor (IGF-1R) monoclonal antibodies (mAbs) were developed for clinical use in treating advanced stage cancers 22,23,24 , including Ganitumab, which remains under investigation as a combination therapy in clinical trials targeting Rhabdomyosarcoma (NCT03041701) and Ewing Sarcoma (NCT02306161), for which it recently received orphan drug status
Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease
TB-500 promotes broader repair and flexibility Dosing synergy: BPC-157: 250500mcg 12x daily (local injection) TB-500: 25mg weekly (divided into 23 doses, SubQ or IM) TB-500 (thymosin beta-4) enhances angiogenesis and cellular differentiation, making it synergistic with BPC-157 in musculoskeletal recovery. Goldstein, A
Maximum benefit: once per month, bi-weekly for those suffering from chronic illness
Does MSM improve immunity
1 2 "Development of Peptide Biopharmaceuticals in Russia"